Quartesian’s 2019 performance yields record revenue and growth

Throughout 2019, Quartesian continues to gain momentum with strong uptake rates for new services and large contract growth. With over 200 customers, including 5 of the top 20 life science companies and 4 of the top 10 CROs, Quartesian remains a valued strategic partner in clinical development – delivering expert on-demand SAS and EDC-savvy resources, high-quality data and an uncompromised focus on efficiency.

To learn more about Quartesian’s 2019 success and hear comments from Quartesian’s CEO and COO, read the full press release here and follow us on Twitter at @Quartesian.

Contact us